We hypothesize that the gain on efficacy would exceed the toxicity cost, especially because the most burdensome part of traditional TIL therapy is the high-dose IL-2 treatment, which should not be needed with IL-2 produced by TILT-123 at tumor site. This evidence concerns the gene IL2 and neoplasm.